Inhibition of human skin phospholipase A2 by "lipocortins" is an indirect effect of substrate/lipocortin interaction. 1993

B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
Department of Dermatology, University of Würzburg Medical School, Germany.

Proteins of the annexin/lipocortin family have been claimed to mediate the anti-inflammatory action of glucocorticosteroids by the inhibition of phospholipases A2. This hypothesis has been challenged by the finding that annexins do not directly interact with the enzyme in a classical enzyme/inhibitor behavior, but more likely block the access of the phospholipase A2 to its substrate by binding to phospholipids. Because former studies with skin phospholipase A2 suggested a specific regulation by annexin-1, we investigated the substrate dependence of this effect. For this purpose phospholipase A2 activities in human epidermis and dermis homogenates were measured in the presence of various amounts of annexins-1, -2, or -5. The respective annexin was preincubated in separate series either with the substrate or with the enzyme. We found a partial inhibition of both epidermal and dermal phospholipase A2 activities with all annexins tested (annexin-5 >> annexin-2 > annexin-1). The inhibitory effect was absolutely dependent on the annexin/phospholipid ratio and occurred only at very high annexin concentrations relative to the amount of substrate. Our data demonstrate that the inhibition of human skin phospholipase A2 by annexins depends on the substrate concentrations, as has been shown for phospholipases A2 of other origins as well. All observations can be explained by the current "substrate depletion model" characterizing the indirect effects of annexins on phospholipase A2 activities. It is therefore rather unlikely that annexins are directly involved in the regulation of phospholipase A2 activity of human skin under physiologic conditions.

UI MeSH Term Description Entries
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D010741 Phospholipases A Phospholipases that hydrolyze one of the acyl groups of phosphoglycerides or glycerophosphatidates.
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D017304 Annexin A5 A protein of the annexin family isolated from human PLACENTA and other tissues. It inhibits cytosolic PHOSPHOLIPASE A2, and displays anticoagulant activity. Annexin V,Placental Anticoagulant Protein I,Anchorin CII,Calphobindin I,Endonexin II,Lipocortin V,Lipocortin-V
D017305 Annexin A1 Protein of the annexin family exhibiting lipid interaction and steroid-inducibility. Annexin I,Calpactin II,Lipocortin I,Chromobindin 9,Lipocortin 1,Renocortin

Related Publications

B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
February 1987, The Journal of biological chemistry,
B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
August 1990, Biological chemistry Hoppe-Seyler,
B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
December 1990, Biochemical Society transactions,
B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
January 1988, Methods in enzymology,
B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
July 1987, FEBS letters,
B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
January 1990, Progress in clinical and biological research,
B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
August 1989, The British journal of dermatology,
B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
December 2006, Analytical biochemistry,
B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
May 1987, FEBS letters,
B C Bastian, and C Sellert, and A Seekamp, and J Römisch, and E P Pâques, and E B Bröcker
October 1989, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!